Loading…
Loading…
ACUR does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ACUR and 80,000+ other tickers.
See exactly how ACUR's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ACUR and 80,000+ other tickers.
Acura Pharmaceuticals, Inc. operates as a drug delivery innovator, dedicated to exploring, developing, and bringing to market novel technologies and products aimed at enhancing medication safety across the United States. Its product portfolio features Oxaydo tablets, a potent Schedule II narcotic prescribed for managing both acute and chronic moderate-to-severe pain. The company also offers the Nexafed line, consisting of pseudoephedrine and acetaminophen tablets, widely utilized as nasal decongestants in a range of over-the-counter and prescription formulations for cold, sinus, and allergy…
Shares of Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR - Get Free Report) crossed above its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $0.00 and traded as high as $0.0001. Acura Pharmaceuticals shares last traded at $0.00, with a volume of 0 shares changing hands.
Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR - Get Free Report)'s share price crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $0.00 and traded as high as $0.0002. Acura Pharmaceuticals shares last traded at $0.0002, with a volume of 800 shares. Acura Pharmaceuticals Trading Down 50.0% About
PALATINE, Ill., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and six months ended June 30, 2021.